Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENCO-BRAF: Encorafenib and Binimetinib in BRAFV600E-mutant Metastatic NSCLC
NCT04526782Phase 2Active, not recruiting
- Sponsor
- IFCT
- Start
- Jan 2021
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of encorafenib, binimetinib in non-small cell lung cancer (NSCLC), sponsored by IFCT. Started Jan 2021; status: active, not recruiting.
02
Drugs
encorafenibbinimetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04526782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04526782.